Twist Bioscience is scaling a silicon-powered synthetic biology platform into a high-growth bio-industrial utility, with strong AI and genomics tailwinds offset by profitability, dilution, and competitive pricing risks.
Twist Bioscience Corporation is a leading synthetic biology firm that has pioneered a proprietary silicon-based DNA synthesis platform.[1, 2] By replacing traditional plastic 96-well plates with a high-density semiconductor silicon chip containing 9,600 nanowells, the company miniaturizes the chemical reactions required to write DNA.[1, 3] This structural innovation reduces the required volume of expensive chemical reagents by approximately 10,000-fold, establishing a robust cost and throughput advantage over legacy commercial synthesizers.[1, 3]
The company generates revenue across three primary areas: Next-Generation Sequencing (NGS) target enrichment tools, Next-Generation DNA Synthesis and Protein Solutions (DSPS or SynBio), and Biopharma Solutions.[1, 2, 4] Monetization includes project-based service fees, recurring reagent kit sales, and strategic partnerships with biopharma customers through upfront licensing, milestone payments, and future royalty streams.[1, 2, 5] Geographically, the business is highly diversified, with the Americas contributing approximately 60% of total sales, Europe, the Middle East, and Africa (EMEA) representing roughly 30%, and the Asia-Pacific (APAC) region accounting for the remaining 8% to 10%.[1, 6, 7]
The diverse customer base includes major biopharmaceutical and biotechnology companies (including nearly all of the top 50 global pharma entities), academic and government research institutions, clinical diagnostics laboratories, and agricultural biotechnology firms.[1, 2, 8] Customers choose Twist Bioscience over legacy alternatives because of its superior price-to-performance ratio.[4] The company offers high-throughput, high-fidelity synthetic DNA with a guaranteed 5-day turnaround time for its "Express Genes" service, drastically accelerating the standard "design-build-test-learn" research cycle.[1, 3, 9] This makes Twist the preferred utility provider for high-volume bio-data workflows, custom diagnostics panels, and AI-driven drug discovery pipelines.[3, 4, 8]
The table below outlines the core revenue-generation segments, geographical exposures, and target customer profiles of the business.
| Revenue Segment | Contribution (%) | Primary Commercial Products & Services | Core Geographies | Target Customers | Why Customers Choose Twist |
|---|---|---|---|---|---|
| Next-Generation Sequencing (NGS) Applications | ~40% to 45% [1, 4] | Target enrichment panels, library preparation kits, clinical-grade assays (TrueAmp, PCR-Free WGS).[1, 2, 10] | Americas (~60%), EMEA (~30%), APAC (~10%).[1] | Clinical diagnostics, liquid biopsy labs, population genetics projects.[8, 9] | High capture efficiency, workflow integration, sequencer-agnostic platforms.[1, 9] |
| DNA Synthesis & Protein Solutions (DSPS) | ~45% to 48% [1, 4] | Synthetic clonal genes, non-clonal fragments, oligo pools, "Express Genes," "Complex Genes".[1, 2, 11] | Americas (~60%), EMEA (~30%), APAC (~10%).[1] | Academic labs, biotechnology startups, agricultural firms.[2, 8] | 10,000x reagent reduction, 5-day guaranteed turnaround, 99.5% sequence acceptance.[1, 3, 6] |
| Biopharma Solutions & Royalties | Remainder [4] | Synthetic antibody libraries, optimization services, milestone-driven CRO partnerships.[1, 2, 4] | Americas (~60%), EMEA (~30%), APAC (~10%).[1] | Tier-1 pharmaceutical firms, tech-bio platforms (AWS BioDiscovery, Benchling).[6, 12] | Massively parallel screening libraries, AI-integrated lab-in-the-loop workflows.[6, 8, 13] |
Twist Bioscience's product portfolio is built systematically to address multiple stages of the biological research continuum.[2, 12] The synthetic biology segment features custom clonal genes, non-clonal fragments, and high-density oligo pools used in genome-wide CRISPR screenings and metabolic engineering.[1, 4, 14] To capture premium-margin, high-velocity research workflows, the company launched its "Express Genes" service, guaranteeing a five-day turnaround time.[1, 3] Additionally, Twist introduced "Complex Genes," extending its synthesis boundaries up to 7,000 base pairs to support advanced gene therapy and nucleic acid therapeutic research.[11]
In the NGS space, the company provides high-throughput target enrichment kits and library preparation tools that isolate specific genomic regions of interest prior to sequencing.[1, 2, 8] These platforms are sequencer-agnostic and support diverse clinical applications, such as liquid biopsy, tumor profiling, and rare disease screening.[2, 9]
The Biopharma division, operating under Twist Biopharma Solutions, offers antibody discovery and optimization services by screening massive, fully synthetic libraries against novel disease targets.[1, 2, 6] Under the leadership of COO Patrick Finn, Twist has initiated an acceptance rate program aimed at eliminating historical bottlenecks associated with highly repetitive or GC-rich sequences.[6] By upgrading the silicon platform to accept sequences of all complexities, the company is targeting a future acceptance rate of 99.5% for clonal genes and 99.9% for all DNA products, capturing a long-tail market of complex sequences that legacy providers historically refuse.[6]
The competitive advantage of Twist Bioscience is anchored in several structural barriers:
* Cost Advantage via Microfluidic Miniaturization: Shifting the chemical assembly of DNA from traditional microtiter plates to a silicon chip enables Twist to write 9,600 oligos in parallel on a single chip, utilizing 99.8% less reagent than legacy synthesis.[1, 3] This yields a structural cost advantage, allowing Twist to synthesize gene fragments at a fraction of the cost of legacy providers.[14]
* High Customer Switching Costs: Twist's custom NGS target enrichment probes and custom clonal genes are deeply integrated into customers' regulated, proprietary workflows, such as commercial cancer assays, diagnostic panels, and clinical drug trials.[8, 9] Replacing Twist as a supplier would require customers to execute costly and time-consuming re-validation studies under strict regulatory oversight, creating a sticky revenue stream.[8, 9]
* Workflow Integration & Digital Ecosystem: Twist has integrated its wet-lab ordering systems directly into major digital research platforms like Benchling and Amazon Web Services (AWS).[6, 12] Through "one-click" ordering in Benchling and acting as the exclusive wet-lab partner for AWS's "Amazon BioDiscovery" platform, Twist has embedded itself in the daily computational workflows of biopharma researchers.[6, 12, 13]
* IP Protection & Distribution Scale: A global portfolio of over 150 patents and trade secrets protects hardware design, chemical flow orchestration, and sequence assembly software.[1] This technical moat is scaled by the Wilsonville "Factory of the Future" facility in Oregon, which tripled the company's production capacity and optimized logistics to defend its turnaround-time advantage.[4, 8]
Twist Bioscience targets multiple large, growing markets across the global bio-economy:
* The global synthetic biology market was valued at approximately $16.94 billion in 2024 and is expected to reach $167.98 billion by 2035, growing at a compound annual growth rate (CAGR) of 23.2%.[14]
* The DNA synthesis market is projected to grow from $5.18 billion in 2025 to $13.06 billion by 2030 (20.2% CAGR).[15] Twist addresses a $4 billion+ serviceable available market (SAM) in DNA Synthesis & Protein Solutions within an $18 billion TAM.[16]
* The NGS applications market targets a $3 billion+ SAM within a $90 billion+ TAM.[16] The submarket for NGS target enrichment is estimated at $1.6 billion, and Twist is actively targeting a 25% share of this market by 2026.[8]
The competitive environment comprises large life-science conglomerates, specialized DNA synthesizers, and emerging benchtop technologies [1, 14]:
* Integrated DNA Technologies (IDT / Danaher): A formidable competitor that expanded its synthetic biology footprint with a 25,000 sq-ft facility in 2024.[14] IDT launched "Rapid Genes" with a five-day turnaround at $0.15 per base pair to compete with Twist's speed.[14] IDT also holds a dominant 63% market share in CRISPR library construction.[14]
* GenScript Biotech Corporation: A low-cost competitor that reported $594.5 million in revenue for 2024.[14] GenScript launched "FLASH Gene" with flat-rate pricing and is developing semiconductor chip-driven technologies to directly challenge Twist’s silicon platform.[14, 17]
* Thermo Fisher Scientific: Utilizes its expansive, integrated product lines to bundle instruments and consumables, retaining corporate accounts through master service agreements.[1, 14]
* Benchtop Synthesizers (DNA Script, Evonetix): Attempting to decentralize the market via automated, enzymatic benchtop systems.[14] While they reduce outsourced oligo demand, they remain constrained on synthesizing longer, complex genes.[1, 14]
Despite aggressive competition, Twist Bioscience is holding and gaining ground.[3, 18] The successful launch of "Express Genes" and its landmark partnership as the exclusive wet-lab CRO partner for Amazon Web Services' "Amazon BioDiscovery" platform have validated Twist's position as the primary high-velocity validation utility for AI-driven biological design.[4, 6]
The table below provides a competitive matrix comparing Twist Bioscience against its primary market rivals.
| Competitor | Core Synthesis Platform | Average Turnaround Time (Clonal Genes) | Pricing Strategy | Key Specialized Dominance | Competitive Trajectory vs. Twist |
|---|---|---|---|---|---|
| Twist Bioscience | Semiconductor Silicon-Based Chip [1, 3] | 5 Business Days (Express Portfolio) [1, 9] | Premium for speed, highly cost-efficient at scale [1, 3] | High-throughput target enrichment, AI drug discovery [6, 8] | Gaining Ground via AWS exclusive partnerships and complex gene acceptance initiative.[6, 11] |
| IDT (Danaher) | Traditional 96-well plastic plates; expanding automation [1, 14] | 5 Business Days (Rapid Genes portfolio) [14] | Volume-based discounts, low-cost baseline [14] | CRISPR library construction (63% market share) [14] | Holding Ground through rapid facility expansions and competitive price matching.[14] |
| GenScript Biotech | Traditional synthesis; investing in semiconductor R&D [14] | Variable (standard); FLASH portfolio offers rapid options [17, 19] | Aggressive per-base discount pricing [1] | Early drug discovery CRO, downstream biologics [19, 20] | Holding Ground in low-cost standard synthesis but lagging in silicon microfluidic scale.[1, 14] |
| Thermo Fisher | Multi-channel centralized automation [1, 19] | Variable | Bundled pricing with lab instrumentation [1] | Master service agreements with major clinical & academic labs [1, 19] | Losing Ground in specialized high-throughput synthetic gene segments to Twist's pure-play speed.[1, 3] |
On May 4, 2026, Twist Bioscience announced its financial results for the fiscal second quarter of 2026 (ended March 31, 2026).[10, 21, 22] The company delivered record revenue, marked by sequential growth and improving unit economics.[10, 21]
Management raised its guidance for the full fiscal year 2026, reflecting solid demand in the first half of the year [10]:
* Total Revenue: Expected to be in the range of $442 million to $447 million (17% to 19% growth), compared to prior guidance of $435 million to $440 million.[10]
* Gross Margin: Projected to exceed 52% for the full fiscal year 2026.[10]
* Adjusted EBITDA: Management reiterated its target to achieve Adjusted EBITDA breakeven by the fourth quarter of fiscal 2026.[10, 21]
The table below breaks down the latest quarterly performance against analyst expectations.
| Metric | Q2 FY2026 Actual ($M) | Consensus Estimate ($M) | Performance vs. Expectations | Key Drivers |
|---|---|---|---|---|
| Total Revenue | $110.7 [21] | $107.6 [23] | Beat (+2.9%) [23] | Strong adoption of Express Genes; AI drug discovery partnerships.[21, 23] |
| DSPS Revenue | $53.3 [21] | $51.0 [18] | Beat (+4.5%) | Accelerated turnaround times; complex sequence acceptance.[1, 6] |
| NGS Revenue | $57.4 [21] | $56.6 | Beat (+1.4%) | Rebound in order volume from major diagnostics partners.[6, 7] |
| Gross Margin | 51.6% [21] | 51.0% | Beat (+60 bps) | High utilization at the Wilsonville facility; favorable product mix.[1, 8] |
| GAAP Net Loss | ($44.0) [21] | ($30.4) [24] | Missed | Unplanned $7.2M litigation settlement charges.[6, 21] |
| EPS | ($0.71) [21] | ($0.49) [23] | Missed (-$0.22) [23] | Higher SG&A overhead and securities class action legal settlement.[6, 21] |
During the earnings call, CEO Dr. Emily Leproust confirmed that Twist remains on track for Adjusted EBITDA breakeven in Q4 FY2026.[10] The land-and-expand strategy is gaining traction, with product shipments reaching 2,583 customers during the quarter (up from 2,431 in Q2 FY25).[10] Additionally, the company physically shipped 300,000 genes during the quarter, compared with 227,000 in the prior year period.[10] CFO Adam Laponis highlighted the ongoing growth of APAC, which now accounts for 8% of total revenue ($9.1 million), signaling international runway.[6]
The stock fell 6.1% immediately following the earnings release, primarily driven by the GAAP EPS miss and cautious comments regarding flat academic research funding.[6, 23] However, the market soon looked past the one-time litigation charge, focus shifting to the upward revision in full-year guidance.[10, 21] Over the subsequent weeks, several analysts upgraded the stock or raised their price targets:
* Leerink Partners upgraded the stock from Market Perform to Outperform, raising its price target to $80.00 from $70.00.[18, 25]
* Robert W. Baird increased its price target to $65.00 from $50.00 (Outperform).[18, 25]
* Barclays reissued an Overweight rating with a $65.00 price target.[18, 25]
* Guggenheim raised its target to $60.00, citing the expansion of the clonal genes portfolio.[11, 25]
By late May 2026, the stock had surged to a new 52-week high of $66.84.[25] At current prices, the stock trades at an Enterprise Value of approximately $4.0 billion [18] and a Price-to-LTM-Sales multiple of 10.6x.[25] This premium multiple is supported by the company's robust 33.1% historical revenue CAGR (FY2020 to FY2025) and expanding gross margins.[3, 9, 26]
The decoupling of the cash-heavy DNA Data Storage segment into Atlas Data Storage in May 2025 has also reshaped the investment thesis.[5, 9] Supported by a $155 million seed round from major venture capital firms, Atlas operates independently, eliminating a substantial R&D expense from Twist’s core financials.[5, 9] Twist retains a minority equity stake, a secured promissory note, milestone-based technology payments, and royalties on future product sales, preserving long-term upside without the associated capital intensity.[5, 9]
To project total returns for Twist Bioscience Corp (TWST) over the next five years (FY2026 to FY2031), three potential scenarios are modeled.
In this scenario, Twist maintains its position in SynBio and NGS target enrichment.[8, 14] Revenue grows at a 15% CAGR from the FY2026 guidance midpoint ($444.5 million) to $894.1 million by FY2031.[10] Gross margins hold above 52%, and operational scale supports a net profit margin of 12% as fixed-cost leverage is achieved.[10] Diluted shares outstanding grow at an annual rate of 1.8% to 67.0 million due to stock-based compensation.[29] As growth matures, the EV/Sales multiple contracts from 10.6x to a conservative 6.0x.[25]
* Future Valuation: $894.1M * 6.0x = $5.36 billion.
* Projected Share Price: $5.36B / 67.0M = $80.00.
In this bullish case, Twist capitalizes on its AWS BioDiscovery partnership, capturing higher-margin biopharma royalties and licensing fees.[4, 6] Revenue grows at a 22% CAGR to $1.20 billion by FY2031. Net margins expand to 18% as high-margin royalties scale.[4] Strong operational cash generation limits share dilution, maintaining outstanding shares at 65.0 million. The market rewards this execution with a premium EV/Sales multiple of 8.5x. This scenario also assumes positive valuation contributions from the Atlas Data Storage spin-out.[5, 9]
* Future Valuation: $1.20B * 8.5x = $10.20 billion.
* Projected Share Price: $10.20B / 65.0M = $156.92.
In this bearish case, Twist experiences price wars with IDT and GenScript, commoditizing short synthetic genes.[1, 14] Enzymatic benchtop systems successfully decentralize academia accounts.[1, 14] Revenue grows at an 8% CAGR to $653.0 million by FY2031. Net margins are squeezed to 5% due to price cuts and persistent litigation.[21] To fund persistent cash burn, Twist relies on dilutive equity financing, pushing outstanding shares to 72.0 million. The multiple contracts to 3.5x EV/Sales.
* Future Valuation: $653.0M * 3.5x = $2.29 billion.
* Projected Share Price: $2.29B / 72.0M = $31.81.
The table below summarizes the quantitative outputs of this scenario modeling.
| Scenario | Revenue in Year 5 ($M) | Margin / Earnings Assumption | Valuation Multiple Assumption | Current Share Price ($) | Implied Future Share Price ($) | 5-Year Total Return (%) | Annualized Return (%) | Subjective Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $1,200.0 | 18% Net / $216.0M Net Income | 8.5x EV/Sales | $67.86 [28] | $156.92 | +131.2% | +18.2% | 30% |
| Base Case | $894.1 | 12% Net / $107.3M Net Income | 6.0x EV/Sales | $67.86 [28] | $80.00 | +17.9% | +3.3% | 50% |
| Low Case | $653.0 | 5% Net / $32.6M Net Income | 3.5x EV/Sales | $67.86 [28] | $31.81 | -53.1% | -14.4% | 20% |
| Weighted Outcome | $937.7 | 12.4% Net / $116.6M Net Income | 6.25x EV/Sales | $67.86 [28] | $93.44 | +37.7% | +6.6% | 100% |
Valuation Bridge & Strategy:
This analysis suggests that Twist Bioscience offers attractive long-term optionality, with the probability-weighted model implying a future share price of $93.44 and an annualized return of 6.6%. The primary driver of future returns is the company's ability to maintain a double-digit growth trajectory while successfully scaling unit economics to achieve sustained profitability.
HIGH-ASYMMETRY OPTIONALITY
To evaluate the qualitative attributes of Twist Bioscience Corp, the business has been rated on ten core operational and financial dimensions, presented in the table below.
| Qualitative Dimension | Score (1-10) | Key Qualitative Drivers |
|---|---|---|
| Management Alignment | 8 / 10 | High insider ownership by CEO Emily Leproust (~846k shares directly owned) [32, 33]; stock-dominated compensation aligns incentives [34]; insider selling is predominantly restricted to mandated 10b5-1 tax withholding trades.[11, 32, 35] |
| Revenue Quality | 7 / 10 | Consumables-driven NGS business generates high recurring revenue [2]; SynBio synthesis revenue is stable but remains lumpy, and biopharma milestones are unpredictable.[2, 36] |
| Market Position | 8 / 10 | Clear market leader in high-throughput DNA synthesis [14]; expanding NGS market share through sequencer-agnostic target enrichment.[8, 9] |
| Growth Outlook | 8 / 10 | Solid secular tailwinds in synthetic biology and clinical genomics [14, 37]; guidance recently upgraded for FY2026, signaling sustained demand.[10, 21] |
| Financial Health | 6 / 10 | Gross margins expanding above 51% [21], but cash reserves of $171.7M are declining [6]; Atlas spin-out helps protect the balance sheet by reducing core cash-burn.[5, 9] |
| Business Viability | 8 / 10 | Robust silicon manufacturing moat protects the business; high switching costs and integration into partner platforms (Benchling, AWS) limit client churn.[3, 4, 9, 12] |
| Capital Allocation | 7 / 10 | Strategic division spin-out (Atlas Data Storage) to preserve cash [5, 9]; internal CapEx is focused on manufacturing automation to drive scale economies.[6] |
| Analyst Sentiment | 9 / 10 | Highly positive Wall Street consensus with a "Strong Buy" rating [38]; several post-earnings target price upgrades to $65.00 - $80.00.[18, 25] |
| Profitability | 4 / 10 | Twist remains GAAP unprofitable due to commercial and SG&A overhead [21]; however, unit economics are improving with Adjusted EBITDA breakeven on track for Q4 FY2026.[10, 21] |
| Track Record | 7 / 10 | Consistent execution with 13 consecutive quarters of sequential revenue growth [10, 21]; historical equity dilution remains a minor negative.[29] |
| Blended Score | 7.2 / 10 | Reflects a highly innovative platform with solid execution and high barriers to entry, balanced by near-term GAAP unprofitability. |
Management is strongly aligned with shareholders, with Dr. Emily Leproust maintaining a direct equity stake of over $58 million, and a stock-heavy incentive structure.[32, 33, 34] This alignment is supported by positive analyst sentiment, which has driven consecutive price target upgrades.[18, 25] The long-term viability of the business is supported by the proprietary silicon chip technology, which provides a durable hardware barrier that is difficult for competitors to replicate.[1, 3, 4]
While revenue growth remains strong, Twist's high commercial SG&A overhead ($76.1 million in Q2 FY2026) continues to limit GAAP profitability, keeping its overall scorecard balanced.[21] Capital allocation remains disciplined, highlighted by the strategic Atlas spin-out to manage cash burn.[5, 9] However, the declining cash runway ($171.7 million) and historical equity dilution remain areas for investors to monitor until the company achieves sustained free cash flow.[6, 29]
ROBUST TECHNOLOGICAL FRANCHISE
Twist Bioscience Corp is transitioning from a high-burn technology developer to a scaled, automated bio-industrial infrastructure leader.[3] By shifting DNA synthesis from plastic plates to silicon semiconductors, the company has established a cost and speed advantage that continues to disrupt legacy workflows.[1, 3, 4] Near-term growth is driven by rising demand in high-throughput AI drug discovery [1, 6], the expansion of sequencer-agnostic target enrichment kits in clinical diagnostics [8, 9], and strategic integrations within major software platforms.[12, 13]
While near-term risks include pricing pressure from IDT and GenScript [1, 14] and cautious academic spending [6, 7], the strategic separation of Atlas Data Storage allows Twist to focus on cash-generative core operations.[5, 9] Twist Bioscience is currently positioned as an innovative biotechnology utility with expanding gross margins and a clear path to commercial scale.[3, 8]
SCALING TO PROFITABILITY
The share price of Twist Bioscience is currently trading at $67.86, displaying a bullish trend comfortably above its 200-day simple moving average of $58.46 and its 50-day moving average of $61.68.[28, 39] The stock recently touched a new 52-week high of $66.84 [25] and subsequently traded near $69.20, driven by its Q2 FY2026 earnings beat and interest in its AI drug discovery exposure.[11, 18, 25] While short-term technical indicators suggest neutral-to-oversold conditions, and routine, non-discretionary executive "sell to cover" trades have drawn investor focus [11, 32, 35], the stock remains in a strong technical uptrend.[11, 39] This technical momentum is supported by positive expectations ahead of its presentation at the William Blair Growth Stock Conference on June 2, 2026.[11, 28]
BULLISH SECULAR TREND
View Twist Bioscience Corporation (TWST) stock page
Loading the interactive version of this report…